Want to join the conversation?
$CELG said its cancer drug received approval to treat patients with newly diagnosed multiple myeloma in Japan. The approval was based on safety and efficacy results from an international phase 3 study, the FIRST trial as the pivotal study, as well as a confirmatory Japanese phase 2 study. This expands upon approval of REVLIMID in 2010.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!